Praxis Precision Medicines Inc Market Cap ($7.96 Billion)
Market Cap & Net Worth: Praxis Precision Medicines Inc (PRAX)
Praxis Precision Medicines Inc market cap. Praxis Precision Medicines Inc (NASDAQ:PRAX) has a market capitalization of $7.96 Billion ($7.96 Billion) as of October 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2560 globally and #946 in its home market, demonstrating a 7.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Praxis Precision Medicines Inc's stock price $285.48 by its total outstanding shares 27878774 (27.88 Million).
Praxis Precision Medicines Inc Market Cap History (2020–2026)
Praxis Precision Medicines Inc market cap history from 2020 to 2026. Data shows change from $23.01 Billion to $7.96 Billion (-6.08% CAGR). Check latest Praxis Precision Medicines Inc stock price today for real-time trading data and today's change.
Index Memberships
Praxis Precision Medicines Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.30% | #60 of 976 |
|
NASDAQ Composite
IXIC
|
$41.45 Trillion | 0.02% | #298 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.85 Trillion | 0.43% | #42 of 263 |
Weight: Praxis Precision Medicines Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Praxis Precision Medicines Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Praxis Precision Medicines Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see how efficiently does Praxis Precision Medicines Inc generate cash for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
250.85x
Praxis Precision Medicines Inc's market cap is 250.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $995.27 Million | $1.46 Million | -$213.07 Million | 679.83x | N/A |
| 2023 | $621.14 Million | $2.45 Million | -$123.28 Million | 253.84x | N/A |
| 2024 | $2.15 Billion | $8.55 Million | -$182.82 Million | 250.85x | N/A |
Competitor Companies of PRAX by Market Capitalization
Companies near Praxis Precision Medicines Inc in the global market cap rankings as of October 30, 2026. See debt-free asset ratio of Praxis Precision Medicines Inc to understand what proportion of total assets are financed by equity.
Key companies related to Praxis Precision Medicines Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #419 globally with a market cap of $67.66 Billion USD ( AU$95.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #500 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $529.69 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $813.27 |
| #419 | CSL Ltd | AU:CSL | $67.66 Billion | AU$197.10 |
| #500 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $214.17 |
Market Capitalization of Praxis Precision Medicines Inc (2020–2026)
Market capitalization of Praxis Precision Medicines Inc from 2020 to today. Between 2020 and today, Praxis Precision Medicines Inc's market cap moved from $23.01 Billion to $ 7.96 Billion, with a yearly change of -6.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.96 Billion | -3.14% |
| 2025 | $8.22 Billion | +282.98% |
| 2024 | $2.15 Billion | +245.42% |
| 2023 | $621.14 Million | -37.59% |
| 2022 | $995.27 Million | -87.92% |
| 2021 | $8.24 Billion | -64.19% |
| 2020 | $23.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 29th, 2026 the market cap of Praxis Precision Medicines Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.96 Billion USD |
| MoneyControl | $7.96 Billion USD |
| MarketWatch | $7.96 Billion USD |
| marketcap.company | $7.96 Billion USD |
| Reuters | $7.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more